Skip to content
Bacil Pharma logo

Bacil Pharma

524516 BSE
Price unavailable

Bacil Pharma (BACPHAR) share price was ₹19.36 at the 28 Oct 2026 close; market capitalisation ₹27.81 Cr; P/E (TTM) 42.09; sector Healthcare. The share price fell 51.9% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue was under ₹1 Cr in both quarters and net profit was −₹0.02 Cr, against ₹0.67 Cr a year earlier (compared with Jun 2025). Promoters held 0.00% of Bacil Pharma in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 43/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹19.36 −18.91 −49.41% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹27.81 Cr
P/E (TTM)
42.09
EBITDA
₹1.00 Cr
Return on Equity
6.27%
Debt to Equity
0
Book Value
₹17.55
EPS (TTM)
₹0.46
52W High
₹61.80
52W Low
₹10.65

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,768.0035.074,24,202 Cr5.080.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,657.5087.652,56,376 Cr15.300.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,609.5072.361,75,331 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,187.70108.091,18,204 Cr22.300.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.6026.291,17,865 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,339.0034.681,11,764 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.5032.711,10,313 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Bacil Pharma (this company)
—42.0928 Cr1.100.00%6.27%3.99%0 Cr1 Cr
Median 8 companies₹1,768.0038.581,18,035 Cr4.720.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

43 Weak
Overall score

Data confidence 89/100

Category scores

Quality Average 49
Returns, margins, earnings quality 24% weight
Valuation Poor 36
Cheap vs sector & own history 26% weight
Financial Health Good 66
Solvency, leverage, coverage 10% weight
Momentum Poor 3
Trend strength, vol-adjusted 13% weight
Ownership Average 50
FII/DII/promoter flows 26% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company is almost debt free.

Weaknesses

2
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 3.18% over last 3 years.

Technical Indicators

Oscillators

Bullish

Bearish
2
Neutral
3
Bullish
4

Overall

Bearish

Bearish
12
Neutral
3
Bullish
4

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
71.43% lower than 3Y

change over 1 year

Net Income Growth
300% higher than 3Y

change over 1 year

Cash Flow Change
77.5%

change over 1 year

EBITDA Margin Change
29.87%

change over 1 year

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0
0
0
0
0
0
0
0
0
0
0
0
0
Expenses
0.03
0.04
0.05
0.06
0.04
0.07
0.06
0.07
0.11
0.03
0.02
0.07
0.02
Operating Profit
-0.03
-0.04
-0.05
-0.06
-0.04
-0.07
-0.06
-0.07
-0.11
-0.03
-0.02
-0.07
-0.02
Other Income
0.05
0.03
0.03
0.02
0.01
0.56
0
0.09
1
0.05
0.06
0.11
0.09
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0.02
-0.01
-0.02
-0.04
-0.03
0.49
-0.06
0.02
0.89
0.02
0.04
0.04
0.07
Tax %
0%
0%
0%
0%
0%
0%
0%
0%
24.72%
0%
0%
-1450%
114.29%
Net Profit
0.02
-0.01
-0.02
-0.04
-0.03
0.48
-0.06
0.02
0.67
0.01
0.04
0.62
-0.02
EPS (₹)
0.03
-0.02
-0.03
-0.07
-0.05
0.81
-0.1
0.01
0.47
0.01
0.03
0.43
-0.01
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0
0
0
0
0
0
0
0
0
0
0
0
0
Expenses
0.11
0.13
0.17
0.29
0.26
0.18
0.16
0.16
0.17
0.19
0.25
0.25
0.14
Operating Profit
-0.11
-0.13
-0.17
-0.29
-0.26
-0.18
-0.16
-0.16
-0.17
-0.19
-0.25
-0.25
-0.14
Other Income
0.08
0.06
0.17
-3.42
-0.07
-0.12
-0.07
-3.7
0.07
0.13
0.66
1.24
0.31
Interest
0
0
0
0.03
0
0.01
0
0
0
0
0
0
0
Depreciation
0
0
0
0.01
0.01
0.01
0
0
0
0
0
0
0
PBT
-0.03
-0.07
0
-3.75
-0.34
-0.32
-0.23
-3.86
-0.1
-0.06
0.41
0.99
0.17
Tax %
0%
0%
—
0%
0%
0%
0%
0%
0%
0%
0%
-57.58%
—
Net Profit
-0.03
-0.07
0
-3.75
-0.34
-0.32
-0.24
-3.86
-0.1
-0.06
0.4
1.56
0.65
EPS (₹)
-0.05
-0.12
0
-6.37
-0.58
-0.54
-0.41
-6.55
-0.17
-0.1
0.28
1.09
0.46
Div. Payout %
0%
0%
—
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
6.53
6.53
6.53
6.53
6.53
6.53
6.53
6.53
6.53
6.53
13.97
13.97
Reserves
-0.06
-0.13
-0.09
-4.29
-4.62
-5.14
-5.14
-5.3
-5.43
-5.31
11.46
10.84
Borrowings
0.14
0.27
0.31
0
0.1
0.17
0.18
0.03
0.02
0.1
0.16
0
Other Liabilities
0.02
0.02
0.02
2.51
2.55
2.55
2.52
0.01
0.01
0.01
0.02
2.58
Total Liabilities
6.63
6.69
6.77
4.75
4.56
4.11
4.09
1.27
1.13
1.33
25.61
27.39
Fixed Assets
0.01
5.25
5.94
2.53
2.53
2.52
2.51
0.01
0.01
0.01
0
0
CWIP
5.88
0
0
0
0
0
0
0
0
0
0
0
Investments
0.51
0.51
0.54
1.15
0.96
0.43
0.37
0.31
0.43
0.61
21.36
24.24
Other Assets
0.23
0.93
0.29
1.07
1.07
1.16
1.21
0.95
0.69
0.71
4.25
3.15
Total Assets
6.63
6.69
6.77
4.75
4.56
4.11
4.09
1.27
1.13
1.33
25.61
27.39
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0.26
0.06
0
1.44
-0.3
-0.38
-0.4
-4.01
-0.15
0
0.4
0.71
Investing
-0.33
-0.05
0.02
-1.2
0.28
0.39
0.53
3.81
-0.12
0.08
0.34
-2.38
Financing
0
0
0
0
-0.16
-0.06
-0.07
0.33
0.06
-0.06
2.08
-0.62
Net Cash Flow
-0.07
0.01
0.02
0.23
-0.18
-0.05
0.06
0.13
-0.2
0.01
2.82
-2.29
Free Cash Flow
0.24
-3.21
0
1.14
-0.3
-0.38
-0.4
-4.01
-0.15
0
0.4
0.71
CFO/OP
-236
-46
0
-497
115
211
250
2,506
88
0
-160
-284
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %
-0.45%
-1.05%
-1.49%
-6.01%
-8.47%
-2.8%
-5.75%
-7.07%
-12.61%
-13.11%
-0.97%
3.93%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Bacil Pharma insights

49 extracted metrics + investor summaries across FY10–FY27.

Shareholding Pattern

Public85.39%Others14.61%As ofSep 2026

Documents

Frequently Asked Questions about Bacil Pharma

What does Bacil Pharma Ltd do?
Bacil Pharma Limited is a Mumbai-registered listed company incorporated in 1987. Although its stated business is pharmaceutical healthcare, it recorded no core operating revenue in FY26 and is currently an investment/other-income-led, non-operating company evaluating future business opportunities...
Where is Bacil Pharma Ltd (BACPHAR) listed?
Bacil Pharma Ltd trades under code 524516 on the BSE.
Which sector does Bacil Pharma Ltd belong to?
Bacil Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Bacil Pharma Ltd?
Bacil Pharma Ltd has a market capitalisation of ₹27.81 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Bacil Pharma Ltd?
Bacil Pharma Ltd trades at a PE ratio of 42.09 as of 28 Oct 2026, on earnings per share of ₹0.46, against a book value of ₹17.55 per share.
What is the 52-week high and low of Bacil Pharma Ltd?
Over the last 52 weeks Bacil Pharma Ltd has traded between ₹10.65 and ₹61.8 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Bacil Pharma Ltd?
Bacil Pharma Ltd reported a return on equity of 6.27%. Its debt-to-equity ratio is 0.00.

Company Information

Bacil Pharma Limited is a Mumbai-registered listed company incorporated in 1987. Although its stated business is pharmaceutical healthcare, it recorded no core operating revenue in FY26 and is currently an investment/other-income-led, non-operating company evaluating future business opportunities.[1] [2]

Website bacilpharma.com
Face Value ₹ 10
Shares Outstanding 1,43,66,999

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524516.md for Bacil Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month